Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorStratigos, A. J.
dc.contributor.authorSekulic, A.
dc.contributor.authorPeris, K.
dc.contributor.authorBechter, O.
dc.contributor.authorDutriaux, C.
dc.contributor.authorKaatz, M.
dc.contributor.authorLewis, K. D.
dc.contributor.authorBasset-Seguin, N.
dc.contributor.authorChang, A. L. S.
dc.contributor.authorDalle, S.
dc.contributor.authorFernandez-Orland, A.
dc.contributor.authorLicitra, L.
dc.contributor.authorRobert, C.
dc.contributor.authorUlrich, C.
dc.contributor.authorHauschild, A.
dc.contributor.authorMigden, M. R.
dc.contributor.authorDummer, R.
dc.contributor.authorLi, S.
dc.contributor.authorBowler, T.
dc.contributor.authorFury, M. G.
dc.contributor.authoraffiliation[Stratigos, A. J.] Natl & Kapodistrian Univ Athens, Andreas Sygros Hosp, Dept Dermatol Venereol, Athens, Greece
dc.contributor.authoraffiliation[Sekulic, A.] Arizona Mayo Clin, Dept Dermatol, Phoenix, AZ USA
dc.contributor.authoraffiliation[Peris, K.] Univ Cattolica Sacro Cuore, Inst Dermatol, Rome, Italy
dc.contributor.authoraffiliation[Peris, K.] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
dc.contributor.authoraffiliation[Bechter, O.] Univ Hosp, Dept Gen Med Oncol, Leuven, Belgium
dc.contributor.authoraffiliation[Dutriaux, C.] Ctr Hosp Univ Bordeaux, Dept Dermatol, Bordeaux, France
dc.contributor.authoraffiliation[Kaatz, M.] SRH Wald Klinikum Gera GmbH, Dept Dermatol, Gera, Germany
dc.contributor.authoraffiliation[Lewis, K. D.] Univ Colorado Hosp, Div Med Oncol, Aurora, CO USA
dc.contributor.authoraffiliation[Basset-Seguin, N.] Hop St Louis, Dept Dermatol, Paris, France
dc.contributor.authoraffiliation[Chang, A. L. S.] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA
dc.contributor.authoraffiliation[Dalle, S.] Ctr Hosp Lyon Sud, Dept Dermatol, Lyon, France
dc.contributor.authoraffiliation[Fernandez-Orland, A.] Hosp Univ Virgen Macarena, Dept Dermatol, Seville, Spain
dc.contributor.authoraffiliation[Licitra, L.] Fdn IRCCS Ist Nazl Tumori, Med Oncol Head & Neck Canc Dept, Milan, Italy
dc.contributor.authoraffiliation[Licitra, L.] Univ Milan, Milan, Italy
dc.contributor.authoraffiliation[Robert, C.] Gustave Roussy Canc Ctr, Dermatol Unit, Villejuif, France
dc.contributor.authoraffiliation[Robert, C.] Paris Saclay Univ, Villejuif, France
dc.contributor.authoraffiliation[Ulrich, C.] Charite, Skin Canc Ctr, Berlin, Germany
dc.contributor.authoraffiliation[Hauschild, A.] Univ Kiel, Dept Dermatol, Kiel, Germany
dc.contributor.authoraffiliation[Migden, M. R.] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
dc.contributor.authoraffiliation[Migden, M. R.] Univ Texas MD Anderson Canc Ctr, Dept & Head & Neck Surg, Houston, TX 77030 USA
dc.contributor.authoraffiliation[Dummer, R.] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
dc.contributor.authoraffiliation[Li, S.] Regeneron Pharmaceut Inc, Clin Sci, Basking Ridge, NJ USA
dc.contributor.authoraffiliation[Bowler, T.] Regeneron Pharmaceut Inc, Clin Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
dc.contributor.authoraffiliation[Fury, M. G.] Regeneron Pharmaceut Inc, Clin Sci, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
dc.contributor.funderRegeneron Pharmaceuticals, Inc.
dc.contributor.funderSanofi
dc.date.accessioned2025-01-07T16:06:05Z
dc.date.available2025-01-07T16:06:05Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2277
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423592/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27616
dc.identifier.wosID573469102675
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS1175-S1176
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePrimary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía